A three-year review of lung cancer patient characteristics in a tertiary hospital

Ghana Med J. 2023 Sep;57(3):167-174. doi: 10.4314/gmj.v57i3.2.

Abstract

Objective: The study sought to determine clinical characteristics and histologic subtypes of a cohort of lung cancer patients in a tertiary facility.

Design: Retrospective review of the medical records of histology-confirmed lung cancer cases at the respiratory clinic over a 3-year period.

Setting: Respiratory Clinic, Korle-Bu Teaching Hospital, Accra, Ghana.

Participants: All adult patients with histologically diagnosed lung cancer were enrolled.

Main outcome measures: Lung cancer histological types.

Results: The proportion of lung cancer cases was 12.4%. The majority were women (57.8%) and the mean age at diagnosis was 55.8±16.0 years. The patients were predominantly non-smokers (61%). Common symptoms were chronic cough and chest pain. More than two-thirds of the cases presented in clinical stages III and IV with the predominant histological subtype being adenocarcinoma in smokers and non-smokers. Genetic testing for epidermal growth factor receptor (EGFR) and Anaplastic Lymphoma kinase (ALK) mutations were largely absent.

Conclusions: The majority of lung cancer patients presented late with advanced disease. Adenocarcinoma was the predominant histological subtype in a predominantly non-smoking population, with an increased prevalence among women less than 60 years. This should encourage testing for genetic mutations to improve patient survival.

Funding: None declared.

Keywords: Anaplastic Lymphoma Kinase (ALK); Epidermal growth factor receptor (EGFR); Lung Cancer.

MeSH terms

  • Adenocarcinoma / epidemiology
  • Adult
  • Aged
  • Aged, 80 and over
  • Chest Pain / etiology
  • Cough / etiology
  • ErbB Receptors / genetics
  • Female
  • Ghana / epidemiology
  • Humans
  • Lung Neoplasms* / epidemiology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Retrospective Studies
  • Smoking* / adverse effects
  • Smoking* / epidemiology
  • Tertiary Care Centers*

Substances

  • ErbB Receptors